{"product_id":"harvard-breast-cancer-new-horizons-current-controversies-2025","title":"Harvard Breast Cancer New Horizons, Current Controversies 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: surgical, and radiation oncologists, breast surgeons\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBreast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease, improvements in diagnostic methods, treatment innovations, and management of breast cancer survivors. The primary goal of the course is to improve the knowledge, competence, and clinical skills of health care professionals who specialize in oncology. As such, the curriculum is well suited for medical, surgical, and radiation oncologists; breast and general surgeons; internists; physician assistants; nurse practitioners; oncology nurses; and other clinicians involved in the care of breast cancer patients.\u003c\/p\u003e\n\u003cp\u003eThis year, we will be again offering an in-person program as well as a livestream for those who still do not feel comfortable traveling to Boston. Continuing with the livestream allows participants to engage with our faculty from the convenience of their own community, be it in Boston or across the globe. This hybrid format worked very well last year and is appropriate given both the range of potential attendees and persistent uncertainty over travel and large group gatherings.\u003c\/p\u003e\n\u003ch3\u003eThe timing of the course for summer 2025 is particularly fortuitous owing to the extraordinary progress happening in breast cancer. In the last two years, we have seen transformative breakthroughs in all types of breast cancer treatment:\u003c\/h3\u003e\n\u003cp\u003eFDA approval of novel antibody-drug conjugates for the treatment of advanced hormone receptor-positive, HER2-positive, and triple-negative breast cancer, with new data showing benefit of these agents in tumor types beyond their initial application.\u003c\/p\u003e\n\u003cp\u003eFDA approval of the AKT pathway inhibitor capivasertib in combination with fulvestrant for patients with hormone receptor-positive, PIK3CA\/AKT\/PTEN-mutant metastatic breast cancer and reported phase III data of another agent in this class (inavolisib).\u003c\/p\u003e\n\u003cp\u003eFDA approval of the CDK4\/6 inhibitor abemaciclib in high-risk, early-stage hormone receptor-positive breast cancer, and mature data showing compelling benefits including overall survival for this class of drugs in advanced breast cancer, as well as preliminary reports of a second agent in this class (ribociclib) with adjuvant efficacy.\u003c\/p\u003e\n\u003cp\u003eFDA approval of a novel antibody-drug conjugate for patients with a HER2-low metastatic breast cancer.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eApply knowledge of recent clinical data together with current expert recommendations to patient selection for new and emerging therapies for advanced breast cancer.\u003c\/p\u003e\n\u003cp\u003eSelect appropriate risk assessment modalities, where applicable, and make evidence-based therapeutic selections for women who are candidates for neoadjuvant or adjuvant therapy and know the limitations of genomic testing.\u003c\/p\u003e\n\u003cp\u003eApply recent clinical data and expert recommendations to the management of women with breast cancer who are treated with mastectomy, including integration of surgical methods, breast reconstruction options, and post-mastectomy radiation if needed.\u003c\/p\u003e\n\u003cp\u003eAssess current practices regarding symptom management during active treatment and in survivorship and consider the needs for fertility and lifestyle counseling among patients with breast cancer and survivors and improve current practices if needed.\u003c\/p\u003e\n\u003cp\u003eEvaluate the genetic and personal risk factors of breast cancer and utilize appropriate genetic testing for hereditary breast cancer.\u003c\/p\u003e\n\u003cp\u003eParticipant Types\u003c\/p\u003e\n\u003cp\u003eNurse Practitioners, Primary Care Physicians, Physician Assistants, Nurses, Pharmacists, and Specialty Physicians\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTheme: Advances in Radiation Therapy, Pathology, and Breast Cancer Management\u003c\/p\u003e\n\u003cp\u003eWelcoming Remarks\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e\n\u003cp\u003eSession I: Radiation Oncology\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003e50 Years of Radiation Therapy\u003c\/p\u003e\n\u003cp\u003eAbram Recht\u003c\/p\u003e\n\u003cp\u003eStandard Radiation Therapy: The Long and the Short\u003c\/p\u003e\n\u003cp\u003eJulia Wong\u003c\/p\u003e\n\u003cp\u003eThe Future of Breast Radiation Therapy\u003c\/p\u003e\n\u003cp\u003eAtif Khan\u003c\/p\u003e\n\u003cp\u003eRadiopharmaceuticals\u003c\/p\u003e\n\u003cp\u003eHeather Jacene\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eAbram Recht, Atif Khan, Julia Wong, Heather Jacene\u003c\/p\u003e\n\u003cp\u003eSession II: Pathology\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eLobular Breast Cancer\u003c\/p\u003e\n\u003cp\u003eStuart Schnitt\u003c\/p\u003e\n\u003cp\u003ectDNA: The Evolving Role for Molecular Diagnostics\u003c\/p\u003e\n\u003cp\u003eStefania Morganti\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eStuart Schnitt, Stefania Morganti\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture\u003c\/p\u003e\n\u003cp\u003eSpeaker(s): Sydney Smith \u0026amp; Julie Bosworth\u003c\/p\u003e\n\u003cp\u003eTopic: What’s New in Supportive Care: Management of Gastrointestinal Side Effects\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eEssentials of Germline Genetics\u003c\/p\u003e\n\u003cp\u003eJudy Garber\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eJulie Bosworth, Sydney Smith, Judy Garber\u003c\/p\u003e\n\u003cp\u003eSchwartz Rounds: A Complex Case\u003c\/p\u003e\n\u003cp\u003eSpeaker: Ann Partridge\u003c\/p\u003e\n\u003cp\u003eTumor Board: Early Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eHarold Burstein, Faina Nakhlis, Julia Wong, Brittany Bychkovsky, Adrienne Waks, Filipa Lynce, Elizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eSession III: HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eNew Approaches in Early Stage HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAdrienne Waks\u003c\/p\u003e\n\u003cp\u003eThe Progress Continues: Late Stage HER2 Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eSarah Sammons\u003c\/p\u003e\n\u003cp\u003eCan We Cure Metastatic Breast Cancer?\u003c\/p\u003e\n\u003cp\u003eNancy Lin\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eSara Tolaney, Sarah Sammons, Nancy Lin, Adrienne Waks\u003c\/p\u003e\n\u003cp\u003eSpecial Lecture\u003c\/p\u003e\n\u003cp\u003eSpeaker(s): Erica Warner, Filipa Lynce, Antonio Giordano, Jennifer Ligibel\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eRacial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype\u003c\/p\u003e\n\u003cp\u003eErica Warner\u003c\/p\u003e\n\u003cp\u003eInflammatory Breast Cancer\u003c\/p\u003e\n\u003cp\u003eFilipa Lynce\u003c\/p\u003e\n\u003cp\u003eEarly Drug Discovery in Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAntonio Giordano\u003c\/p\u003e\n\u003cp\u003eLifestyle\/Diet\/Exercise in Breast Cancer Patients\u003c\/p\u003e\n\u003cp\u003eJennifer Ligibel\u003c\/p\u003e\n\u003cp\u003eReception\u003c\/p\u003e\n\u003cp\u003eTheme: Surgical Interventions and Advanced Breast Cancer Treatment\u003c\/p\u003e\n\u003cp\u003eSession IV: Surgery\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eOncoplastic Reconstruction: Common Indications and Outcomes\u003c\/p\u003e\n\u003cp\u003eIndranil Sinha\u003c\/p\u003e\n\u003cp\u003eThe Axilla After Neoadjuvant Therapy: How Much Is Too Much?\u003c\/p\u003e\n\u003cp\u003eElizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eImplications of the SOUND Trial\u003c\/p\u003e\n\u003cp\u003eOlga Kantor\u003c\/p\u003e\n\u003cp\u003eCryoblation Instead of Surgery\u003c\/p\u003e\n\u003cp\u003eFrancys Verdial\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eBarbara Smith, Indranil Sinha, Olga Kantor, Francys Verdial, Elizabeth Mittendorf\u003c\/p\u003e\n\u003cp\u003eSchlager Lecture: Immunotherapy in Early Breast Cancer: Today and Tomorrow\u003c\/p\u003e\n\u003cp\u003eSpeaker: Marleen Kok\u003c\/p\u003e\n\u003cp\u003eSession V: Triple Negative Breast Cancer (TNBC)\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eSmall TNBCs: How Small Is Small Enough?\u003c\/p\u003e\n\u003cp\u003eSteven Isakoff\u003c\/p\u003e\n\u003cp\u003eAntibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer\u003c\/p\u003e\n\u003cp\u003eAna Garrido-Castro\u003c\/p\u003e\n\u003cp\u003eImmunotherapy in TNBC\u003c\/p\u003e\n\u003cp\u003eGuilherme Nader Marta\u003c\/p\u003e\n\u003cp\u003eManaging Endocrine Side Effects of Immunotherapy\u003c\/p\u003e\n\u003cp\u003eElad Sharon\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eSteven Isakoff, Ana Garrido-Castro, Guilherme Nader Marta, Elad Sharon\u003c\/p\u003e\n\u003cp\u003eTumor Board: Advanced Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eRachel Freedman, Barbara Smith, Sarah Sammons, Erica Mayer, Laura Spring, Leticia Varella, Guilherme Nader Marta, Daniel Abravanel\u003c\/p\u003e\n\u003cp\u003eSession VI: ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eTime\u003c\/p\u003e\n\u003cp\u003eSession Title\u003c\/p\u003e\n\u003cp\u003eSpeaker(s)\u003c\/p\u003e\n\u003cp\u003eNew Approaches in Early ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003eErica Mayer\u003c\/p\u003e\n\u003cp\u003ePI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target\u003c\/p\u003e\n\u003cp\u003eDejan Juric\u003c\/p\u003e\n\u003cp\u003eAdvanced ER Positive Breast Cancer: A Surfeit of Choices\u003c\/p\u003e\n\u003cp\u003eSeth Wander\u003c\/p\u003e\n\u003cp\u003eEmerging Antibody Drug Conjugates in ER Positive Breast Cancer\u003c\/p\u003e\n\u003cp\u003ePaolo Tarantino\u003c\/p\u003e\n\u003cp\u003eQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003eErica Mayer, Seth Wander, Paolo Tarantino, Dejan Juric\u003c\/p\u003e\n\u003cp\u003eCDK4\/6: Which One? For Whom? – Debate\u003c\/p\u003e\n\u003cp\u003eSpeakers: Shana Berwick, Laura Spring\u003c\/p\u003e\n\u003cp\u003eASCO Highlights\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e\n\u003cp\u003eClosing Remarks\u003c\/p\u003e\n\u003cp\u003eSpeaker: Harold Burstein\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405776244932,"sku":null,"price":78.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Harvard-Breast-Cancer-New-Horizons-Current-Controversies-2025.jpg?v=1784215978","url":"https:\/\/medicalcoursespro.com\/products\/harvard-breast-cancer-new-horizons-current-controversies-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}